Matinas Biopharma’s (MTNB) “Buy” Rating Reiterated at Roth Capital
MTNB opened at $1.06 on Monday. Matinas Biopharma has a 1-year low of $0.32 and a 1-year high of $1.48.
Matinas Biopharma (NASDAQ:MTNB) last announced its quarterly earnings data on Monday, November 12th. The company reported ($0.03) EPS for the quarter.
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.
Featured Article: QQQ ETF
Receive News & Ratings for Matinas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.